Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Myriad Genetics, Inc., 10x Genomics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Myriad Genetics, Inc., 10x Genomics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Myriad Genetics, Inc., 10x Genomics and Inc.

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3’ gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Latest Biotechnology and Myriad Genetics, Inc., 10x Genomics, Inc. Stock News

As of July 31, 2026, Myriad Genetics, Inc. had a $273.6 million market capitalization, compared to the Biotechnology median of $252.6 million. Myriad Genetics, Inc.’s stock is down 53.5% in 2026, down 49% in the previous five trading days and down 29.38% in the past year.

Currently, Myriad Genetics, Inc. does not have a price-earnings ratio. Myriad Genetics, Inc.’s trailing 12-month revenue is $829.0 million with a -14.0% net profit margin. Year-over-year quarterly sales growth most recently was 2.3%. Analysts expect adjusted earnings to reach $0.080 per share for the current fiscal year. Myriad Genetics, Inc. does not currently pay a dividend.

As of July 31, 2026, 10x Genomics, Inc. had a $6.0 billion market cap, putting it in the 70th percentile of all stocks. 10x Genomics, Inc.’s stock is up 189.8% in 2026, up 2.2% in the previous five trading days and up 239.83% in the past year.

Currently, 10x Genomics, Inc. does not have a price-earnings ratio. 10x Genomics, Inc.’s trailing 12-month revenue is $638.8 million with a -3.5% net profit margin. Year-over-year quarterly sales growth most recently was -2.6%. Analysts expect adjusted earnings to reach $0.000 per share for the current fiscal year. 10x Genomics, Inc. does not currently pay a dividend.

How We Compare Myriad Genetics, Inc., 10x Genomics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Myriad Genetics, Inc., 10x Genomics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Myriad Genetics, Inc., 10x Genomics and Inc. Stock Value Grades

Company	Ticker	Value
Myriad Genetics, Inc.	MYGN	A
10x Genomics, Inc.	TXG	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Myriad Genetics, Inc. has a Value Score of 84, which is Deep Value. 10x Genomics, Inc. has a Value Score of 7, which is Ultra Expensive.

The Value Stock Winner: Myriad Genetics, Inc.

As you can clearly see from the Value Grade breakdown above, Myriad Genetics, Inc. is considered to have better value than 10x Genomics, Inc.. For investors who focus solely on a company’s valuation, Myriad Genetics, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Myriad Genetics, Inc., 10x Genomics and Inc.’s Momentum Grades

Company	Ticker	Momentum
Myriad Genetics, Inc.	MYGN	D
10x Genomics, Inc.	TXG	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Myriad Genetics, Inc. has a Momentum Score of 27, which is Weak. 10x Genomics, Inc. has a Momentum Score of 99, which is Very Strong.

The Momentum Grade Winner: 10x Genomics, Inc.

As you can clearly see from the Momentum Grade breakdown above, 10x Genomics, Inc. is considered to have stronger momentum compared to Myriad Genetics, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, 10x Genomics, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Myriad Genetics, Inc., 10x Genomics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Myriad Genetics, Inc.	MYGN	C
10x Genomics, Inc.	TXG	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Myriad Genetics, Inc. has a Earnings Estimate Score of 55, which is Neutral. 10x Genomics, Inc. has a Earnings Estimate Score of 66, which is Positive.

The Earnings Estimate Revisions Grade Winner: 10x Genomics, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, 10x Genomics, Inc. has a better Earnings Estimate Revisions Grade than Myriad Genetics, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, 10x Genomics, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Myriad Genetics, Inc., 10x Genomics and Inc. Grades

In addition to Value, Momentum and Estimate Revisions, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Myriad Genetics, Inc., 10x Genomics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Myriad Genetics, Inc., 10x Genomics or Inc. Stock?

Overall, Myriad Genetics, Inc. stock has a Value Score of 84, Momentum Score of 27 and Estimate Revisions Score of 55.

10x Genomics, Inc. stock has a Value Score of 7, Momentum Score of 99 and Estimate Revisions Score of 66.

Comparing Myriad Genetics, Inc., 10x Genomics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.